Rybelsus® reduces cardiovascular events in diabetes patients

Novo Nordisk has shared findings from the SOUL trial, showing that Rybelsus® (oral semaglutide) significantly lowers the risk of serious heart events in adults with type 2 diabetes and cardiovascular conditions. This study was presented at the American College of Cardiology’s annual meeting in Chicago. The trial achieved its main goal, showing a 14% reduction in major adverse cardiovascular events such as heart attacks and strokes among those using Rybelsus® compared to a placebo. These outcomes highlight the importance of new treatments for managing cardiovascular risks in diabetic patients. Experts, including Dr. Darren McGuire, emphasized that heart-related issues are common in individuals with type 2 diabetes. The SOUL trial's results offer hope by providing an oral treatment option to improve cardiovascular health in these patients. The safety profile of Rybelsus® was consistent with previous research, revealing no new safety issues. Serious adverse events were lower in those taking Rybelsus® compared to the placebo group. Novo Nordisk has applied for regulatory approvals to expand the use of Rybelsus® based on these results, with decisions expected later this year.